

ISTITUTO CLINICO  
HUMANITAS

Istituto di Ricovero e Cura  
a Carattere Scientifico



# Quando è lecito passare ai VAD


## Le scelte strategiche



**Alessandro Barbone**  
UO di CARDIOCHIRURGIA  
Istituto Clinico Humanitas  
Rozzano - Mi

# ECMO

**Vena Femorale**



**VAD**

**Ossigenatore**

**Arteria Femorale**

# Lungs White-Out

ISTITUTO CLINICO  
HUMANITAS  
Istituto di Ricovero e Cura  
a Carattere Scientifico





Alla luce dei risultati ottenuti dalla terapia sostitutiva con VAD in pazienti con cardiomiopatia cronica (65-90% dei pazienti trapiantati con successo), si è rafforzata l'idea di un possibile miglioramento dell'outcome dei pazienti con IMA-shock cardiogeno con l'utilizzo di questi device

# Assistenze ventricolari

ISTITUTO CLINICO  
HUMANITAS  
Istituto di Ricovero e Cura  
a Carattere Scientifico



- To duplicate that mechanically is going to be a very difficult thing to do.

Denton A. Cooley, MD

# Ventricular Assist Device

ISTITUTO CLINICO  
HUMANITAS  
Istituto di Ricovero e Cura  
a Carattere Scientifico



Ventricolo  
Sinistro

POMPA

Circolo  
Arterioso


Impiantabile

VAD


Paracorporeo

# Ventricular Assist Device

ISTITUTO CLINICO  
HUMANITAS  
Istituto di Ricovero e Cura  
a Carattere Scientifico





# Assistenza Meccanica al Circolo




# Short term Percutanei


ISTITUTO CLINICO  
HUMANITAS  
Istituto di Ricovero e Cura  
a Carattere Scientifico



# Sopravvivenza???



# Sopravvivenza???



**Figure 3** Meta-analysis showing the relative risk of crude 30-day mortality with use of percutaneous left ventricular assist devices. Random effects model was used for meta-analysis. Relative risks with 95% confidence intervals are presented on the right of the figure. IABP, intra-aortic balloon pump; LVAD, left ventricular assist device.



# Prognosis After the Implantation of an Intra-Aortic Balloon Pump in Cardiac Surgery Calculated With a New Score

Harald Hausmann, MD; Evgenij V. Potapov, MD; Andreas Koster, MD; Thomas Krabatsch, MD; Julia Stein; Ruhi Yeter, MD; Marian Kukucka, MD; Ralf Sodian, MD; Hermann Kuppe, MD, PhD; Roland Hetzer, MD, PhD

(*Circulation*. 2002;106[suppl I]:I-203-I-206.)

**TABLE 3. Results of Multivariate Analysis**

Parameter	Odds Ratio (OR)	Range (OR)	<i>P</i>
Adrenaline dose $>0.5 \mu\text{g/kg/BW/min}$	6.6	2.3–18.8	0.0005
Diuresis $<100 \text{ ml}$	2.5	1.2–5.4	0.026
$\text{SVO}_2 <60\%$	2.5	1.0–6.3	0.048
LAP $>15 \text{ mm Hg}$	3.0	1.1–8.5	0.036

Multivariate analysis showed 4 parameters as statistically significant for the prediction of survival or death 1 hour after IABP implantation in patients with cardiac low-output syndrome in cardiac surgery. All other parameters were not significant.

N.B.: Urine output under maximum diuretic treatment  
Mixed venous saturation with a minimum hemoglobin blood level of 8 g/dL

# IABP Score

## Parameter of IABP Score

Parameter		Score Points
Adrenaline	$\leq 0.5 \mu\text{g/kgBW/min}$	0
Adrenaline	$> 0.5 \mu\text{g/kgBW/min}$	1
Diuresis	$\geq 100 \text{ mL/hour}$	0
Diuresis	$< 100 \text{ mL/hour}$	1
SVO <sub>2</sub>	$\geq 60\%$	0
SVO <sub>2</sub>	$< 60\%$	1
LAP	$\leq 15 \text{ mmHg}$	0
LAP	$> 15 \text{ mmHg}$	1


} Adrenalina X2

IABP score formula: adrenaline dose  $\times$  2 + diuresis/hour + SVO<sub>2</sub> + LAP.

Example: A patient with adrenaline dose  $0.7 \mu\text{g/kgBW/min}$ , diuresis  $70 \text{ mL/hour}$ , SVO<sub>2</sub>  $63\%$ , LAP  $12 \text{ mmHg}$  =  $1 \times 2 + 1 + 0 + 0 = 3$  score points.

IABP = intra-aortic balloon pump; BW = body weight; SVO<sub>2</sub> = mixed venous saturation; LAP = left atrial pressure.

# Score Points



No. of patients	195	85	51	20	28	12
% of patients	50	22	13	5	7	3

The probability of survival dependent on the IABP. The score and the 30-day survival rate is calculated for the primary investigated group (n391) of patients.

# Quale Paziente?


- Solo e solo se!?!? – almeno teoricamente  
– candidabile al trapianto???




- Quale futuro in assistenza ???

# OZ Score For Survival


Variable	Relative risk	P value	Weighting
Ventilated	5.3	<.0001	4
Postcardiotomy	3.3	<.0001	2
Pre-LVAD	3.3	<.0001	2
CVP >16 mm Hg	2.1	.04	1
PT >16 s	2.1	.02	1



# INTERMACS® Survival



# INTERMACS® for DT



- Fondamentale assicurare un supporto adeguato per evitare la MOF (?Periferico)?
  - Controllare Sanguinamento
  - Protezione polmonare
    - Pig Tail Trans Valvolare Aortico
- A 72h Valutazione Generale:
  - Scarse possibilità di svezzamento entro 7 gg
    - Conversione in supporto centralizzato
  - Buone possibilità di Recovery entro 7 gg
    - Si prosegue supporto e svezzamento

- Importanza del tempo intercorso fra evento (IMA) ed impianto
  - Prima che si manifestino segni di disfunzione d'organo
  - Impianto precoce è un fattore prognostico importante per un miglior outcome

- Recovery
  - Casi sporadici di svezamento dal device

- Funzione ventricolo destro
  - Uso di LVAD sufficiente al supporto
  - Raramente paziente necessita di supporto destro

## ● Quale paziente?

- ▣ Ottimizzazione terapia medica
- ▣ Rivascolarizzazione
- ▣ IABP
- ▣ Funzione d'organo conservata
- ▣ Candidabile al trapianto cardiaco?!?!?

## ● Quale device?

- Levitronix® - LVAD-ECMO

## ● Quale approccio

- Sternotomico LVAD (*atrio sin-aorta*) – Fem/Fem ECMO

## ● Svezzamento


- Modalità di svezzamento
  - Recovery
  - Trapianto



? *Supporto Meccanico  
Destination Therapy*

# ECMO

**Vena Femorale**



**VAD**

**Ossigenatore**

**Arteria Femorale**





